380,000 square feet of facilities envisioned as
creative tech hub where leading software, engineering, and
bioscience talent can solve key problems to accelerate the
discovery of new antibody treatments
AbCellera (Nasdaq: ABCL), a technology company that has
developed a centralized operating system for next-generation
antibody discovery and development, today announced it has broken
ground on an expanded global headquarters in its home city of
Vancouver in anticipation of adding hundreds of employees to its
current 250-person workforce over the next few years.
“We’re building state-of-the-art facilities in Vancouver to
accelerate the development of new antibody therapies with biotech
and pharma partners from around the world,” said Carl Hansen,
Ph.D., CEO and President of AbCellera. “We intend for this
technology campus to serve as a place where talented people can
contribute to dramatically improving and accelerating antibody
discovery for the benefit of patients everywhere.”
Located on 4th Avenue between Columbia and Manitoba Streets in
Mount Pleasant, the company’s planned tech campus includes two
facilities totaling 380,000 square feet that will be developed in
partnership with the Dayhu Group and Beedie. The facilities are
expected to be completed in 2023 and 2024.
“As a Vancouver-based company, AbCellera’s success in leading
the fight against COVID-19 underscores how our city has emerged as
an innovation hub where tech companies can grow and thrive,” said
Vancouver Mayor Kennedy Stewart. “The tech sector is a key economic
driver for our city, and this announcement ensures that one of our
most successful anchor companies will play a pivotal role in
creating new jobs, diversifying our economy, and commercializing
made-in-BC innovations – all while protecting us from current and
emerging health challenges."
AbCellera’s antibody drug discovery platform uses microfluidics,
machine learning, computation, custom robotics, and automation to
search and analyze natural immune systems at record speed and
depth. Hansen noted that the complexity of the technology stack,
along with the fact that it is being used in entirely new ways to
search, decode, and analyze antibodies, requires a uniquely skilled
workforce.
“Vancouver is home to a wealth of talent and a network of
world-leading tech companies and startups,” said Véronique Lecault,
Ph.D., AbCellera’s Chief Operating Officer. “We see this new site
as a creative hub for engineers, software developers, data
scientists, biologists and bioinformaticians to collaborate,
innovate, and push the frontiers of technology. Our company puts
significant value on ambitious, adventurous thinkers who are
energized by solving hard, important problems in entirely new
ways.”
AbCellera’s long-term vision in Vancouver includes building
Canada’s first clinical-grade Good Manufacturing Practice (GMP)
antibody manufacturing facility, which will provide technology and
infrastructure to help Canada respond to future pandemics.
Vancouver is a fast-growing technology center in North America,
attracting startups with a business environment friendly to young
companies, and luring top talent with a sophisticated urban
lifestyle, extraordinary outdoor amenities, and stunning natural
landscapes.
About Dayhu Group of Companies
Dayhu Group of Companies is a leading real estate investment,
development, and property management company with over four million
square feet of industrial, commercial and retail properties across
Western Canada. Founded in 1956, Dayhu is a Vancouver-based,
family-managed and owned business. For more information, please
visit https://dayhu.com/.
About Beedie
Founded in 1954, Beedie is Western Canada’s largest private
industrial developer and property manager, having completed more
than 30 million square feet of new development, with an
ever-expanding portfolio of over 11 million square feet. With over
six decades of building for good, Beedie is also one of the Lower
Mainland’s most reputable residential developers having completed
several significant, large-scale master-planned communities and
mixed-use projects. For more information, please visit
https://www.beedie.ca/.
About AbCellera Biologics
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit
www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429006110/en/
Media: Jessica Yingling, Ph.D.; media@abcellera.com,
+1(236)521-6774 Corporate Development: Murray McCutcheon,
Ph.D.; corpdev@abcellera.com, +1(604)559-9005 Investor
Relations: Melanie Solomon; ir@abcellera.com,
+1(778)729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024